Improving prawn survival rates from 51% to 70% PLUS positive metabolic growth PLUS better feed-conversion is transformational. RIC can put a premium price on Novacq - and the feedstock it is blended into.
Ridley CEO Tim Hart is genuinely excited. Shareholders should be too.
Ooops! on the compromised prawn feed trials. Having to destock the trial ponds while the trial is underway is a brilliant failure, but probably delayed comprehensive scientific analysis by a year. Hart says second-round trial results will be out 1QFY18 - I think a little later.
I am impressed. Market likes it too.
GLTAH
Ash
Ann: NOVACQ(TM) TRIALS DELIVER 37% UPLIFT IN PRAWN SURVIVAL RATES, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RIC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.80 |
Change
0.030(1.08%) |
Mkt cap ! $795.8M | |||
| Open | High | Low | Value | Volume |
| $2.79 | $2.84 | $2.78 | $959.4K | 341.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $2.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.81 | 1932 | 2 |
View Market Depth
| Last trade - 16.10pm 28/11/2024 (20 minute delay) ? |
| RIC (ASX) Chart |
